Interpretation of the 2025 ACC/AHA guidelines for the management of adults with congenital heart disease
- VernacularTitle:《2025 ACC/AHA成人先天性心脏病管理指南》解读
- Author:
Jing LING
1
,
2
;
Jiaxiong WU
1
,
2
;
Runzhang LIANG
1
,
2
;
Zirui PENG
1
,
2
;
Haiyun YUAN
1
,
2
;
Shusheng WEN
1
,
2
Author Information
1. Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, P. R. China
2. Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangzhou, 510080, P. R. China
- Publication Type:Journal Article
- Keywords:
Adult congenital heart disease;
lifelong management;
pulmonary arterial hypertension;
multidisciplinary team;
pregnancy and reproduction;
arrhythmia;
guideline interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(06):874-883
- CountryChina
- Language:Chinese
-
Abstract:
With the rapid advancements in surgical and interventional therapies, over 90% of children with congenital heart disease can now survive into adulthood with appropriate treatment. As a rapidly expanding population, adult congenital heart disease (ACHD) patients often present with complex anatomical abnormalities and post-procedural complications, posing significant long-term management challenges for clinicians. The American College of Cardiology and American Heart Association jointly released the 2025 guidelines for the management of adult congenital heart disease, which represents a comprehensive and fundamental update following the inaugural 2008 edition. This new guideline not only integrates the latest evidence-based data but also marks a paradigm shift in ACHD management, from a disease-centered approach to a patient-centered lifelong continuum of care. This article aims to provide an interpretation of the guidelines from the perspective of a cardiac surgeon to provide references for the management of various disease subtypes.
